Centene Corporation, a healthcare enterprise based in Saint Louis, Missouri, serves under-insured and uninsured families, commercial organizations, and military families. With a market cap of $15.3 billion, Centene operates through Medicaid, Medicare, Commercial, and Other segments, making it a large-cap stock in the U.S. healthcare industry.

Despite being a major healthcare plan provider, Centene’s stock has dropped significantly, plunging 59.5% from its 52-week high and 43.7% over the past three months, underperforming compared to the Health Care Select Sector SPDR Fund. The stock has traded below its moving averages, signaling a bearish trend.

Centene faced a massive 40.4% stock price drop in one trading session after withdrawing its 2025 earnings guidance due to unexpected enrollment trends and rising patient costs. The company’s adjusted earnings outlook was slashed by $2.75 per share, causing a sell-off. Concerns about ACA economics and investor confidence in managed-care models arose.

Centene has also lagged behind its peer, Humana Inc., in stock performance, raising concerns about its sustainability. Analysts have a consensus rating of “Hold” for CNC stock, with a mean price target of $34.19 suggesting a potential 9.3% upside from current levels.

Read more at Yahoo Finance: How Is Centene’s Stock Performance Compared to Other Healthcare Stocks?